Neuromyelitis Optica Overview
Learn About Neuromyelitis Optica
Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.
No genes associated with neuromyelitis optica have been identified. However, a small percentage of people with this condition have a family member who is also affected, which indicates that there may be one or more genetic changes that increase susceptibility. It is thought that the inheritance of this condition is complex and that many environmental and genetic factors are involved in the development of the condition.
Neuromyelitis optica affects approximately 1 to 2 per 100,000 people worldwide. Women are affected by this condition more frequently than men.
Neuromyelitis optica is usually not inherited. Rarely, this condition is passed through generations in families, but the inheritance pattern is unknown.
University Of Virginia Physicians Group
Brian Weinshenker is a Neurologist in Charlottesville, Virginia. Dr. Weinshenker is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Transverse Myelitis, Neuromyelitis Optica, Optic Neuritis, and Multiple Sclerosis (MS). Dr. Weinshenker is currently accepting new patients.
Kazuo Fujihara practices in Fukushima, Japan. Mr. Fujihara is rated as an Elite expert by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Neuromyelitis Optica, Transverse Myelitis, Optic Neuritis, Myelitis, and Thymectomy.
Romain Marignier practices in Lyon, France. Mr. Marignier is rated as an Elite expert by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Optic Neuritis, Transverse Myelitis, Neuromyelitis Optica, and Multiple Sclerosis (MS).
Summary: A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).
Summary: The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging. It leverages advanced multiparametric brain and spinal cord imaging at high (3T) and ultra-high magnetic fields (7T) to assess structural, functional, metabolic, and mesoscale changes in the central nervous system (CN...
Published Date: March 01, 2015
Published By: National Institutes of Health